Table 2. Clinical trials of concurrent TOP1 drugs with thoracic radiotherapy for SCLC.

Study description	No. of patients	Chemotherapy regimen	Radiation dose	Toxicity	Response
Phase I (52)	17 (all LS)	Irinotecan + cisplatin	60 Gy in 3 split courses of 20 Gy in 10 daily fractions	Fatigue	94% (4 CR, 11 PR)
Phase II (53)	100 (43 LS, 57 ES)	Topotecan + carboplatin +paclitaxel	45 Gy in 25 daily fractions for LD	Neutropenia, thrombocytopenia, fatigue	LS -93% ES -88%
Phase II (54)	78 (all LS)	Topotecan + carboplatin +paclitaxel	61.2 Gy in 34 daily fractions	Neutropenia, thrombocytopenia, fatigue fatal pneumonitis	51% CR SV: 20 months

SCLC = small cell lung cancer; LS = limited-stage; ES = extensive-stage; CR = complete response; SV = median survival.